We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$26M
5
NVO
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$46.3B
$10.7M 0.73%
33,860
-4,163
-11% -$1.48M
DHR icon
27
Danaher
DHR
$152B
$10.7M 0.73%
38,429
-2,426
-6% -$642K
CNC icon
28
Centene
CNC
$32B
$10.2M 0.7%
134,959
+19,139
+17% +$1.4M
ELV icon
29
Elevance Health
ELV
$85.5B
$10.1M 0.69%
19,465
+4,808
+33% +$2.57M
FTRE icon
30
Fortrea Holdings
FTRE
$1.79B
$9.16M 0.63%
+457,967
New +$10.8M
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.11M 0.62%
+124,491
New +$9.36M
EOLS icon
32
Evolus
EOLS
$587M
$7.34M 0.5%
453,061
-121,401
-21% -$1.7M
BHVN icon
33
Biohaven
BHVN
$2.33B
$6.62M 0.45%
+132,537
New +$5.16M
ARQT icon
34
Arcutis Biotherapeutics
ARQT
$2.99B
$6.45M 0.44%
693,263
-144,584
-17% -$1.43M
STRO icon
35
Sutro Biopharma
STRO
$339M
$6.37M 0.44%
184,199
+10,286
+6% +$403K
BKD icon
36
Brookdale Senior Living
BKD
$2.8B
$5.85M 0.4%
861,268
-685,574
-44% -$4.89M
NAMS icon
37
NewAmsterdam Pharma
NAMS
$3.1B
$5.1M 0.35%
307,357
-22,533
-7% -$390K
FNA
38
DELISTED
Paragon 28, Inc.
FNA
$5M 0.34%
+749,213
New +$5.67M
GOSS icon
39
Gossamer Bio
GOSS
$83.2M
$4.91M 0.34%
4,978,458
-505,690
-9% -$486K
TSVT
40
DELISTED
2seventy bio
TSVT
$4.71M 0.32%
998,079
-109,664
-10% -$495K
KPTI icon
41
Karyopharm Therapeutics
KPTI
$42.4M
$4.6M 0.32%
369,859
+37,380
+11% +$465K
AVTR icon
42
Avantor
AVTR
$9.86B
$4.36M 0.3%
168,369
+42,975
+34% +$1.05M
BCRX icon
43
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.07M 0.28%
535,405
-617,168
-54% -$4.69M
ICLR icon
44
Icon
ICLR
$13.1B
$3.93M 0.27%
13,668
+1,026
+8% +$324K
KURA icon
45
Kura Oncology
KURA
$1.13B
$3.76M 0.26%
192,398
+120,081
+166% +$2.43M
MOH icon
46
Molina Healthcare
MOH
$10.4B
$3.65M 0.25%
10,588
-7,689
-42% -$2.54M
MRUS
47
DELISTED
Merus
MRUS
$3.41M 0.23%
68,258
+1,784
+3% +$93.1K
STAA icon
48
STAAR Surgical
STAA
$1.11B
$3.39M 0.23%
+91,199
New +$3.4M
PBYI icon
49
Puma Biotechnology
PBYI
$468M
$3.3M 0.23%
1,293,257
-35,197
-3% -$107K
ZLAB icon
50
Zai Lab
ZLAB
$2.93B
$3.26M 0.22%
+135,219
New +$2.56M
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.